Last reviewed · How we verify
18-month regimen containing 6 anti-TB drugs
18-month regimen containing 6 anti-TB drugs is a Small molecule drug developed by Beijing Chest Hospital. It is currently FDA-approved.
The 18-month regimen containing 6 anti-TB drugs, marketed by Beijing Chest Hospital, holds a unique position in the tuberculosis treatment landscape. The key composition patent, set to expire in 2028, provides a significant period of market exclusivity. However, the lack of detailed clinical trial results and revenue data poses a primary risk in assessing the regimen's long-term market viability and competitive edge.
At a glance
| Generic name | 18-month regimen containing 6 anti-TB drugs |
|---|---|
| Sponsor | Beijing Chest Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18-month regimen containing 6 anti-TB drugs CI brief — competitive landscape report
- 18-month regimen containing 6 anti-TB drugs updates RSS · CI watch RSS
- Beijing Chest Hospital portfolio CI